Long-term outcomes of co-administration of CD19 and CD22 CAR-T cell therapy in pediatric patients with relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia

Background: ALL. Methods: CR), complete molecular remission (CMR), relapse-free survival (RFS), and overall survival (OS) were among the important outcomes that were evaluated with a data cutoff of October 1, 2025. Results: CR and CMR of 100 and 77.8%, respectively. Two patients underwent consolidative allogeneic stem cell transplant (allo-HSCT). Notably, six patients achieved sustained CHR without allo-HSCT. At a median follow-up of 54.93 months (range, 16.83-71.6 months), the 4-year OS and RFS were 91.7 and 66.7%. No treatment-related deaths occurred from CAR-T toxicity. Conclusion: ALL, with manageable toxicity. However, these results should be considered hypothesis-generating and require validation in larger, controlled studies. Clinical Trial Registration: https://www.chictr.org.cn/showproj.html?proj=52403, ChiCTR2000032211.